3rd Annual West Cancer Center Oncology Conference - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

3rd Annual West Cancer Center Oncology Conference

WEST Oncology Conference – at Graceland®

Not a member of My prIME? Join now for instant access.

Explore the latest practice-changing data on women’s cancers, genitourinary malignancies, disparities in cancer care, gastrointestinal cancers, head and neck cancers, and lung cancer with these downloadable slides from the 3rd Annual West Cancer Center Oncology Conference – at Graceland on October 27 and 28, 2017, in Memphis, Tennessee.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Oct 31, 2017

Expiration Date

Oct 31, 2018

Gastrointestinal Cancer

Review of gastrointestinal (GI) carcinoid tumors: Latest therapies

Featured Expert: N. Arvind Dasari, MD

HIPEC: An exploration of the data

Featured Expert: Jeremiah Deneve, DO, FACS

Emerging concepts in the multidisciplinary management of rectal cancer

Featured Expert: Thomas J. George, Jr, MD, FACP

Front-line therapy and beyond for metastatic colorectal cancer: Novel targets

Featured Expert: Wells Messersmith, MD, FACP

Emerging therapies in hepatocellular carcinoma

Featured Expert: Andrew X. Zhu, MD, PhD

Genitourinary Malignancies

Molecular approaches to genitourinary (GU) oncology and beyond

Featured Expert: Petros Grivas, MD, PhD

Immunotherapy in GU oncology

Featured Expert: Daniel P. Petrylak, MD

Head and Neck Cancer

De-escalation of therapy in HPV-related oropharyngeal cancer

Featured Expert: Ezra Cohen, MD

Treatment of salivary gland cancers

Featured Expert: M. Boyd Gillespie, MD, MSc, FACS

Immunotherapy in the treatment of head and neck cancers

Featured Expert: Maura Gillison, MD, PhD

Keynote

AJCC updates and innovations: Hot off the press

Featured Expert: Mahul B. Amin, MD

Drive to eliminate disparities in cancer care delivery

Featured Expert: Edith P. Mitchell, MD, FACP, FCPP

Lung Cancer

Individualization of advanced lung cancer

Featured Expert: Leora Horn, MD

Optimal treatment of stage IA lung cancer in the era of low-dose computed tomography lung cancer screening

Featured Expert: Puneeth Iyengar, MD, PhD

Immunotherapy in lung cancer: Breaking into a curative role?

Featured Expert: Howard L. (Jack) West, MD

Women's Cancer

Novel targeted therapies and immunotherapy in ovarian cancer

Featured Expert: Robert L. Coleman, MD, FACOG, FACS

Hormone receptors: A broader understanding (CK, AR, ESR1)

Featured Expert: Anthony Elias, MD

Evolving concepts in breast surgery in multidisciplinary care

Featured Expert: Tina Hieken, MD, FACS

Emerging targets in breast cancer – TNBC

Featured Expert: Andrew Seidman, MD

Updates in HER2-positive breast cancer

Featured Expert: Andrew Seidman, MD

This educational activity is specifically designed to meet the needs of practicing medical oncologists, hematologists, surgeons, radiation oncologists, pathologists, nurses, and other healthcare professionals involved in the treatment of cancer.

  • Identify novel targeted and immunologic approaches to therapy for breast and ovarian cancers
  • Describe the role of nurses in counseling patients with cancer and integrating treatment recommendations to optimize care
  • Identify strategies to prevent and manage the treatment-related adverse events of targeted therapies and immunotherapies to improve tolerability and maintain quality of life
  • Assess emerging targeted and immunologic therapies for genitourinary malignancies, including prostate and renal cell cancer
  • Integrate recent findings on healthcare disparities into optimal therapy selection for individual patients with cancer
  • Identify optimal therapies for patients with gastrointestinal malignancies such as carcinoid tumors, colorectal cancer, and hepatocellular carcinoma
  • Select optimal approaches to therapy for head and neck cancers, including considerations for immunotherapy

This educational activity is supported by grants from Merck and Co, Inc. and Novartis Oncology.

Enduring Material From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Amin has disclosed that he has received payment for lectures from Genomic Health. He also received fees for participation in advisory boards and/or study participation from Cell Max, Otsuka Pharmaceuticals, and Urogen. He also disclosed pending participation on an advisory board for Precipio Lab. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ballo has disclosed that he has received consulting fees, payment for lectures, and fees for participation in advisory or review activities from Novocure. He also received support for travel to meetings from Elekta. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cohen has disclosed that he has received consulting fees from AstraZeneca; Bristol-Myers Squibb; Eisai; Human Longetivity,Inc.; Merck; and Pfizer. He received fees for participation in advisory or review activities from AstraZeneca, Bristol-Myers Squibb, Eisai, Merck, and Pfizer. He also received stock or stock options from Human Longevity, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Coleman has disclosed that he has received consulting fees from AbbVie; Debiopharma; Genmab; ImmunoGen; Merrimack; Navigant Consulting; Perthera; Vaniam Group, LLC; and Verastem. He received payment for lectures from Onc Live and Roche. He received fees for serving on a scientific advisory board from AstraZeneca; Bayer Healthcare, Inc.; Caris Life Sciences; Cerulean; Clovis Oncology; GamaMabs; Janssen; Novocure; Precision Oncology; Roche; and Tesaro. He also received funded research from Array Bio Pharmaceuticals, AstraZeneca, Clovis Oncology, EMD Serono, Gradalis, Janssen, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Dasari has disclosed that he has received research funding and fees for participation in advisory or review activities from Ipsen and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Deneve has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Elias has disclosed receipt of consulting fees from Genentech. He also disclosed receipt of research funding for clinical trials from Astellas, CytRx, Immune Design, and Innocrin. He also disclosed stock or stock options in Abbott, AbbVie, Allergan, Celgene, Gilead, Lilly, Merck, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Fenton has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Fine has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Fleming has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr George has disclosed that he has received consulting fees from Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gillespie has disclosed that he has consulted for Cook Medical and Omniguide. He has received consulting fees from Inspire Medical. He also received research funding from ImThera and Zelegent. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gillson has disclosed receipt of consulting fees or honorarium from Bristol-Myers Squibb and Celgene. She has also disclosed receipt of support for travel to meetings from Bristol-Myers Squibb. She also disclosed receipt of research funding to her institution for researching funding for clinical research from Amgen, AstraZeneca, Bristol-Myers Squibb, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Grivas has disclosed that he has received consulting fees and fees for participation in advisory or review activities from AstraZeneca, Biocept, Bristol-Myers Squibb, Clovis Oncology, EMD Serono, Exelixis, Genentech, and Merck & Co. He has received payment for lectures from Bristol-Myers Squibb. He also received research funding from AstraZeneca; Bayer; Genentech; Merck & Co.; Mirati; Oncogenex; and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gupta has disclosed that he has received fees for participation in advisory or review activities from Exelixis. He also received stock or stock options from EDAP. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hieken has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Horn has disclosed that she has received consulting fees and fees for participation in advisory or advisory activities from AstraZeneca, AbbVie, Bristol-Myers Squibb, Genentech, and Merck. She has received support for travel to meetings from Boehringer Ingelheim. She also received research funding from AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Lilly, Merck, and Takeda. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Iyengar has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Robert Koch has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Messersmith has disclosed he is the local principal investigator for research funding received by the University of Colorado from Aduro, Alexo, D3 Pharma, Immunomedics, Incyte, Millennium/Takeda, OncoMed, Pfizer, and Roche/Genentech. He also disclosed receipt of fees for participation in advisory or review activities from Gilead DMSC and Purdue Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mitchell has disclosed that she has received fees for participation in advisory or review activities from Novartis. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Petrylak has disclosed that he has received consulting fees from Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson and Johnson, Medivation, Millinneum, Pfizer, Roche Laboratories, Sanofi Aventis, and Tyme Pharmaceuticals. He received research funding from Agensys, Dendreon, Eli Lilly, Johnson and Johnson, Merck, Millinneum, OncoGenex, Progenics, Roche Laboratories, and Sanofi Aventis. He also received stock or stock options from Bellicum and Tyme Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Schwartzberg has disclosed that he has received consulting fees or honorarium from Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Seidman has disclosed that he has received consulting fees or honorarium from Eisai, Genentech, Novartis, and Pfizer. He has received payment for lectures from Celgene, Eisai, Genentech, Genomic Health, Novartis, and Pfizer. He has received research funding from Bayer and Novartis. He also received fees for participation in advisory or advisory activities from Eisai, Genentech, Pfizer, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Shibata has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Somer has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vaena has disclosed that he has received fees for participation in advisory or review activities from AstraZeneca and Exelixis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr VanderWalde has disclosed that he has been a contracted employee for George Clinical and Vector Oncology. He has received research funding from Amgen. He also received fees for participation in advisory or advisory activities from Amgen, AstraZeneca, and Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vidal has disclosed that he has received payment for lectures from AstraZeneca and Pfizer. He also received fees for participation in advisory or review activities from Eli Lilly and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Weksler has disclosed that he has received consulting fees from Intuitive Surgical. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr West has disclosed that he has received consulting fees from Ariad, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech/Roche, Merck, PharmaMar, and Takeda. He received payment for lectures from Ariad, Bristol-Myers Squibb, and Genentech/Roche. He also received fees for participation in advisory or review activities from AstraZeneca, Bristol-Myers Squibb, and Celgene. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Zhu has disclosed that he has received consulting fees or honoraria from Bayer, Bristol-Myers Squibb, Eisai, Lilly, Merck, Novartis, and Sanofi. He also received research funding from Bayer, Lilly, and Novartis.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Elizabeth Cameron, PhD- (scientific content reviewer/planner) – no relevant financial relationships
  • Brooke Balun, MSN, APRN-BC, AOCNP (lead nurse planner) – – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.